This page shows the latest Alexion Pharma news and features for those working in and with pharma, biotech and healthcare.
The deal means AZ will immediately gain assets within Alexion’s commercial portfolio, estimated to be worth around $6bn. ... Rare disease is increasingly becoming an area of focus for big pharma, with the Alexion acquisition marking AZ’s first major
Additional shares will be tied to various milestones. Alexion has added to its rare blood disorder pipeline with a $930m agreement to buy smaller biotech Achillion Pharma. ... The drug currently accounts for more than 80% of Alexion’s sales, but is
Massachusetts. The company was unveiled yesterday by its co-founders David Hallal and Vikas Sinha, previously last chief exec and chief financial officer respectively of Alexion, with ex-Bluebird Bio chief ... Hallal and Sinha left Alexion under a cloud
The CHMP recommended 13 medicines last Friday, including Ultomiris, Alexion’s follow-up to its rare disease blockbuster Soliris, and GSK’s single pill, two-drug HIV regimen, Dovato. ... Dova Pharma’s Doptelet (avatrombopag) for the treatment of
Alexion already has a follow-on complement inhibitor to be the next generation replacement for Soliris. ... With Soliris, Alexion has demonstrated the transformative impact of complement inhibition on multiple serious and debilitating diseases.
Alexion has agreed a $1.2bn takeover of US biotech Syntimmune that will add another clinical-stage rare disease drug to its R&D pipeline. ... in the early stages of growth – Alexion has been fixated on bolstering its pipeline.
More from news
Approximately 0 fully matching, plus 16 partially matching documents found.
He has held previous commercial and operational roles with Alexion Pharma in Europe, Europe Area Markets, Emerging Markets and recently, before moving to GSK was the General Manager for MEA.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Judith Reinsdorf recently worked at Johnson Controls. Alexion Pharmaceuticals has appointed Judith Reinsdorf to its board of directors following her role as executive vice president and general counsel of Johnson Controls. ... David Brennan, chairman of
Camilla Harder Hartvig will lead commercial activities from Zurich, Switzerland. Alexion Pharma has appointed Camilla Harder Hartvig as its senior vice president and head of its EMEAC region. ... Alexion’s global business, and look forward to
suited to lead Alexion as we embark on our next exciting phase of growth. ... We are also delighted that Dave Anderson is joining Alexion as our new chief financial officer.
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....